Overview

Qlaris Phase 2 Study in NTG Patients

Status:
Not yet recruiting

Trial end date:
2025-03-07

Target enrollment:

Participant gender:

Summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Qlaris Bio, Inc.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions